Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC By Ogkologos - September 10, 2026 46 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR 如何捐赠头发来帮助癌症患者 April 13, 2022 Coverage for Breast Cancer Genetic Marker Testing is Still Being Denied... July 20, 2021 Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with... August 17, 2026 How My Metastatic Cancer Diagnosis Led Me to a Full-Time Career... July 15, 2021 Load more HOT NEWS Study Links Non-Diet Soda Consumption with a Higher Risk of Death... Summer Sun Safety Tips What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials ESMO Congress 2023, 20-24 October 2023 Madrid, Spain
